Phibro Animal Health (NASDAQ:PAHC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.

According to Zacks, “Phibro ended  second-quarter fiscal 2018 on a mixed note, with bottom line exceeding the Zacks Consensus Estimate and revenues declining marginally on a year-over-year basis. Segment-wise, a persistent decline in Mineral Nutrition segment sales is likely to prove a drag. Customer consolidation can also adversely affect Phibro’s revenues. Moreover, headwinds such as unfavorable currency movement and tough competitive scenario continue to pose threats. Over the past three months, Phibro has been trading below the broader industry. However, on a positive note, Animal Health remained the key contributing business, delivering positive growth on a year-over-year basis. We are also encouraged by the expansion in the gross margin in the reported quarter.”

Several other equities analysts have also recently weighed in on PAHC. Piper Jaffray Companies set a $41.00 price objective on shares of Phibro Animal Health and gave the stock a “buy” rating in a research report on Friday, October 6th. ValuEngine cut shares of Phibro Animal Health from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. Finally, BidaskClub cut shares of Phibro Animal Health from a “hold” rating to a “sell” rating in a research report on Saturday, December 2nd. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $38.25.

Phibro Animal Health (NASDAQ PAHC) traded up $0.45 during midday trading on Monday, reaching $35.30. 59,400 shares of the company’s stock traded hands, compared to its average volume of 98,725. Phibro Animal Health has a 12-month low of $26.10 and a 12-month high of $40.25. The company has a debt-to-equity ratio of 1.91, a quick ratio of 1.85 and a current ratio of 3.26. The stock has a market cap of $1,418.46, a PE ratio of 20.76, a price-to-earnings-growth ratio of 4.12 and a beta of 1.27.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Monday, November 6th. The company reported $0.38 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.01. Phibro Animal Health had a net margin of 8.87% and a return on equity of 42.75%. The firm had revenue of $193.40 million for the quarter, compared to analysts’ expectations of $189.89 million. During the same period in the previous year, the company posted $0.36 EPS. The company’s quarterly revenue was up 2.9% compared to the same quarter last year. equities research analysts expect that Phibro Animal Health will post 1.57 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of PAHC. Schwab Charles Investment Management Inc. grew its holdings in shares of Phibro Animal Health by 1.9% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 144,235 shares of the company’s stock valued at $5,344,000 after acquiring an additional 2,721 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Phibro Animal Health by 4.1% during the 2nd quarter. Rhumbline Advisers now owns 36,185 shares of the company’s stock valued at $1,341,000 after acquiring an additional 1,418 shares in the last quarter. State of Wisconsin Investment Board purchased a new position in shares of Phibro Animal Health during the 2nd quarter valued at $519,000. Bank of New York Mellon Corp grew its holdings in shares of Phibro Animal Health by 1.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 353,098 shares of the company’s stock valued at $13,082,000 after acquiring an additional 5,441 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Phibro Animal Health by 10.1% during the 2nd quarter. Legal & General Group Plc now owns 34,100 shares of the company’s stock valued at $1,264,000 after acquiring an additional 3,123 shares in the last quarter. Institutional investors and hedge funds own 48.42% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Phibro Animal Health (PAHC) Stock Rating Upgraded by Zacks Investment Research” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.watchlistnews.com/phibro-animal-health-pahc-stock-rating-upgraded-by-zacks-investment-research/1798662.html.

About Phibro Animal Health

Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.

Get a free copy of the Zacks research report on Phibro Animal Health (PAHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with Analyst Ratings Network's FREE daily email newsletter.